Skip to main content
$1.69 $0.05 (3.0%)

04:00 PM EST on 11/28/23

G1 Therapeutics (NASDAQ:GTHX)

CAPS Rating: No stars

Current Price $1.69 Mkt Cap $87.6M
Open $1.63 P/E Ratio -1.15
Prev. Close $1.69 Div. (Yield) $0.00 (0.0%)
Daily Range $1.60 - $1.71 Volume 13,170
52-Wk Range $1.08 - $8.40 Avg. Daily Vol. 512,787


How do you think NASDAQ:GTHX will perform against the market?

Add Stock to CAPS Watchlist

All Players

19 Outperform
0 Underperform

All-Star Players

1 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:GTHX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mdriver78 (65.09)
Submitted December 16, 2020

The company, G1 Therapeutics (NASDAQ: GTHX) sits in a sweet spot valuation-wise — cancer biotech companies with valuations between $500 million and $1 billion often are the best performers going into an FDA decision.That valuation is big enough to… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


Fools bullish on NASDAQ:GTHX are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about GTHX.


Member Avatar chrismakesmoney (< 20) Submitted: 4/9/2022 2:44:39 PM : Outperform Start Price: $8.08 NASDAQ:GTHX Score: -81.52

Approved after receiving breakthrough destination during Covid for small cell lung cancer. The drug COSELA halts the harmful effects of chemo induced myelosuppression. COSELA may very well turn out to be a blockbuster on all the other indication the drug can be use for. Including Breast cancer which has shown remarkable results and bladder and colon cancers. It may become the standard of care for all chemothearpy patients. With a patent extending to 2035 and designed and invented by a very well known respected government scientist. The stock looks very intriguing. Sales where slow to start because there partner was not equipped to sell the drug. Now they have a new sales team of 38 in place with the keys to the top accounts in onocology with 500 years plus experience and big time management including Jack Bailey the new ceo and the former President from Glaksosmithkine at the helm.


Member Avatar mdriver78 (65.09) Submitted: 12/16/2020 11:35:41 AM : Outperform Start Price: $19.55 NASDAQ:GTHX Score: -114.23

The company, G1 Therapeutics (NASDAQ: GTHX) sits in a sweet spot valuation-wise — cancer biotech companies with valuations between $500 million and $1 billion often are the best performers going into an FDA decision.

That valuation is big enough to suggest a good likelihood of an FDA approval, while still being small enough to produce big gains should it occur.

The company’s drug, trilaciclib, is designed to protect bone marrow cells from being ravaged by chemotherapy drugs. It has been tested in patients receiving chemo drugs for lung cancer. The company recently reported significant improvement in overall survival for patients using the drug. And data have been strong enough to prompt G1 to file an FDA application.

Trilaciclib is also in clinical trials for patients with breast and colorectal cancers. Moreover, G1 has two other compounds in four additional cancer trials.

Sounding the alarm as it detects a spike in activity as insiders position themselves ahead of the company’s FDA approval date — set for Feb. 15, 2021.

Insiders are often in the best position to judge the prospects for a new drug before an FDA event, and a spike like this one suggests that sentiment has turned very bullish.

Moreover, this unusual activity hasn’t just been high for a session or two. It has been high all month!


Member Avatar TMFSpiffyPop (99.64) Submitted: 7/28/2017 2:45:03 PM : Outperform Start Price: $14.59 NASDAQ:GTHX Score: -172.80

Picking mainly just to remind myself to research further. Outperform.


Find the members with the highest scoring picks in GTHX.

Score Leader


NFender (99.85) Score: +160.15

The Score Leader is the player with the highest score across all their picks in GTHX.

Member Name Member
Call Time
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. chrismakesmoney < 20 4/11/2022 Outperform 5Y $8.08 -79.08% +2.44% -81.52 1 Comment
Boat6458 < 20 11/4/2021 Outperform 5Y $15.91 -89.38% -2.24% -87.14 0 Comment
Gmoney70 40.44 7/23/2021 Outperform 5Y $18.48 -90.85% +3.98% -94.83 0 Comment
losj < 20 3/25/2021 Outperform 5Y $19.86 -91.49% +17.57% -109.06 0 Comment
Quills19 < 20 2/11/2021 Outperform 1Y $30.79 -94.51% +16.32% -110.83 0 Comment
Nafi < 20 2/12/2021 Outperform 5Y $30.80 -94.51% +16.69% -111.21 0 Comment
kfassini < 20 2/26/2021 Outperform 5Y $21.89 -92.28% +19.41% -111.69 0 Comment
bonjourmesamis < 20 2/4/2021 Outperform 5Y $28.12 -93.99% +18.79% -112.78 0 Comment
stereotyp72 58.02 11/23/2020 Outperform 5Y $12.65 -86.64% +27.36% -114.00 0 Comment
mdriver78 65.09 12/16/2020 Outperform 5Y $19.55 -91.36% +22.87% -114.23 2 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GTHX.